CoreLogic, Inc. (CLGX) Forms $48.13 Double Bottom; Pointstate Capital LP Upped Nektar Therapeutics (NKTR) Holding By $138.38 Million

Nektar Therapeutics (NASDAQ:NKTR) Logo

Pointstate Capital Lp increased Nektar Therapeutics (NKTR) stake by 148.41% reported in 2017Q4 SEC filing. Pointstate Capital Lp acquired 2.35M shares as Nektar Therapeutics (NKTR)’s stock rose 80.22%. The Pointstate Capital Lp holds 3.93 million shares with $234.44 million value, up from 1.58M last quarter. Nektar Therapeutics now has $13.55 billion valuation. The stock increased 1.94% or $1.6 during the last trading session, reaching $84.19. About 1.63M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 27, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

CoreLogic, Inc. (CLGX) formed double bottom with $46.69 target or 3.00% below today’s $48.13 share price. CoreLogic, Inc. (CLGX) has $3.92 billion valuation. The stock increased 9.94% or $4.35 during the last trading session, reaching $48.13. About 1.60M shares traded or 228.81% up from the average. CoreLogic, Inc. (NYSE:CLGX) has risen 15.62% since April 27, 2017 and is uptrending. It has outperformed by 4.07% the S&P500.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It dropped, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Pnc Service Group Inc has invested 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Paloma Ptnrs Management reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Parallax Volatility Advisers Lp has 22,554 shares. Manufacturers Life Insur Com The has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Deutsche Bancshares Ag holds 0.01% or 370,002 shares in its portfolio. Fincl Bank Of New York Mellon Corporation holds 1.97M shares. Iowa-based Cambridge Research has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Fortaleza Asset Inc has 6,560 shares. Guggenheim Cap Limited Liability Corp reported 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). First Light Asset Mngmt Ltd Liability Corporation stated it has 351,741 shares or 5.76% of all its holdings. Schwab Charles owns 802,474 shares or 0.04% of their US portfolio. Miles Capital Incorporated stated it has 0.29% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Dekabank Deutsche Girozentrale stated it has 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Rhenman And Partners Asset Mgmt holds 2.85% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 353,503 shares. Kbc Group Nv accumulated 24,716 shares or 0.01% of the stock.

Pointstate Capital Lp decreased United Rentals Inc (NYSE:URI) stake by 119,316 shares to 635,669 valued at $109.28 million in 2017Q4. It also reduced T Mobile Us Inc (Call) (NYSE:TMUS) stake by 100,000 shares and now owns 50,000 shares. Alphabet Inc (Call) was reduced too.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 27 analyst reports since August 6, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of NKTR in report on Monday, April 9 with “Buy” rating. As per Friday, April 13, the company rating was maintained by PiperJaffray. H.C. Wainwright reinitiated the shares of NKTR in report on Monday, April 2 with “Buy” rating. As per Tuesday, November 8, the company rating was initiated by Aegis Capital. The firm earned “Hold” rating on Wednesday, August 26 by TheStreet. The rating was maintained by Roth Capital on Wednesday, August 9 with “Buy”. Piper Jaffray maintained Nektar Therapeutics (NASDAQ:NKTR) on Thursday, January 7 with “Overweight” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Mizuho on Friday, April 6. The firm earned “Buy” rating on Tuesday, July 18 by J.P. Morgan. The rating was maintained by Mizuho on Thursday, March 29 with “Buy”.

Since December 13, 2017, it had 0 insider buys, and 18 sales for $68.39 million activity. GREER R SCOTT had sold 30,000 shares worth $2.77M on Friday, April 6. KUEBLER CHRISTOPHER A sold 40,000 shares worth $3.90M. $21.85M worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Nicholson John. On Friday, February 16 Thomsen Jillian B. sold $211,082 worth of Nektar Therapeutics (NASDAQ:NKTR) or 2,545 shares. 160,000 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $14.89 million were sold by Doberstein Stephen K. Lingnau Lutz also sold $3.05M worth of Nektar Therapeutics (NASDAQ:NKTR) on Thursday, April 5. 83,333 shares were sold by ROBIN HOWARD W, worth $6.32M on Monday, January 22.

Since March 8, 2018, it had 0 buys, and 2 selling transactions for $1.20 million activity. SANDO BARRY M sold $63,618 worth of CoreLogic, Inc. (NYSE:CLGX) on Thursday, March 8.

Among 12 analysts covering CoreLogic Inc (NYSE:CLGX), 3 have Buy rating, 3 Sell and 6 Hold. Therefore 25% are positive. CoreLogic Inc has $54.0 highest and $33.0 lowest target. $44.45’s average target is -7.65% below currents $48.13 stock price. CoreLogic Inc had 30 analyst reports since September 1, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Thursday, August 18. The company was maintained on Thursday, March 24 by Macquarie Research. The company was maintained on Thursday, October 26 by Piper Jaffray. As per Tuesday, July 25, the company rating was maintained by Oppenheimer. Robert W. Baird maintained it with “Hold” rating and $47.0 target in Tuesday, February 6 report. Compass Point maintained CoreLogic, Inc. (NYSE:CLGX) on Tuesday, February 6 with “Sell” rating. The stock of CoreLogic, Inc. (NYSE:CLGX) has “Hold” rating given on Thursday, January 18 by Piper Jaffray. The company was maintained on Monday, March 5 by Keefe Bruyette & Woods. The stock has “Buy” rating by Barclays Capital on Wednesday, June 7. The rating was maintained by Wood on Monday, September 19 with “Market Perform”.

Investors sentiment decreased to 1 in 2017 Q4. Its down 0.03, from 1.03 in 2017Q3. It fall, as 23 investors sold CoreLogic, Inc. shares while 81 reduced holdings. 49 funds opened positions while 55 raised stakes. 70.61 million shares or 1.62% less from 71.77 million shares in 2017Q3 were reported. Thompson Siegel & Walmsley has invested 0.31% of its portfolio in CoreLogic, Inc. (NYSE:CLGX). The Illinois-based Balyasny Asset Mgmt Limited Liability Company has invested 0% in CoreLogic, Inc. (NYSE:CLGX). Cwm Ltd Llc holds 180 shares or 0% of its portfolio. First Republic Mgmt has 0% invested in CoreLogic, Inc. (NYSE:CLGX) for 7,864 shares. Morgan Stanley reported 149,235 shares. Delta Asset Management Ltd Liability Corporation Tn invested in 0.03% or 4,500 shares. Becker Management, a Oregon-based fund reported 4,793 shares. First Mercantile Tru holds 0.01% in CoreLogic, Inc. (NYSE:CLGX) or 1,200 shares. Rhumbline Advisers has invested 0.02% in CoreLogic, Inc. (NYSE:CLGX). State Street Corp has invested 0.01% in CoreLogic, Inc. (NYSE:CLGX). Huntington Bankshares has 0% invested in CoreLogic, Inc. (NYSE:CLGX) for 4,640 shares. Gemmer Asset Management Ltd Liability Company owns 347 shares. Tower Rech Capital Limited Liability Company (Trc) holds 634 shares or 0% of its portfolio. Moreover, Greenwood Associates Limited Liability Company has 0.05% invested in CoreLogic, Inc. (NYSE:CLGX) for 4,350 shares. Deutsche State Bank Ag accumulated 266,625 shares or 0.01% of the stock.

CoreLogic, Inc. (NYSE:CLGX) Institutional Positions Chart